Skip to content
Search

Latest Stories

Top Stories

How the government can solve America's obesity epidemic

How the government can solve America's obesity epidemic
Getty Images

Pearl is a clinical professor of plastic surgery at the Stanford University School of Medicine and is on the faculty of the Stanford Graduate School of Business. He is a former CEO of The Permanente Medical Group.

Dying younger. Living harder. Going broke. It is difficult to overstate the longitudinal effects of excess weight in America.


An estimated seven in ten Americans are overweight or obese. The combination, according to the National Institutes of Health, results in an estimated 300,000 preventable deaths per year with extreme obesity lowering life expectancy by 14 years on average.

Added weight not only makes everyday life more difficult, but it also produces serious health consequences that include cardiovascular disease, diabetes, musculoskeletal disorders and cancer. In total, obesity costs an estimated $260 billion annually in inpatient and outpatient care.

Whether weight gain is caused primarily by genetics, societal influences or individual will, scientists aren’t altogether sure. What’s clear, however, is that most efforts to lose weight ultimately fail.

New Hope In Diabetes Drugs

Ozempic, one of a new class of medications, has been shown in studies to spur significant weight loss. The others include Mounjaro, Rybelsus and Wegovy with several new (and convenient, pill-based) options in development.

A Heavy Price For Weight Loss  

Last year, more than five million Americans were prescribed one of these drugs for weight reduction.

The annual price of treatment ranges from $12,000 (Mounjaro) to upwards of $16,000 per year (Wegovy). As a result, most users are either wealthy or have generous health-insurance coverage.

But as more Americans seek these medications for moderate weight loss, not diabetes, insurers have started clamping down. They’ve issued threatening letters to doctors, warning they’ll be referred to state regulatory boards for writing “off-label” prescriptions.

The Ozempic Paradox: Highly Effective But Unaffordable

Ozempic and other medications that help with weight loss are part of an ongoing national debate in which two competing truths collide.

The first truth is that these drugs work, leading to significant and sustained weight reduction: 14 to 25 pounds per individual on average during the medication course. And while they’re not a replacement for proper nutrition, exercise or healthier living, they do reduce the likelihood of heart attack, stroke and cancer.

Second, despite the medical opportunity at hand, making these drugs available to all 100 million obese American adults would prove cost prohibitive for businesses, private insurers and the government.

This means that the medications could drastically rollback the nation’s $260 billion in obesity-related medical expenses each year, but prescribing them at today’s prices would cost more than $1.5 trillion annually—increasing national healthcare expenditures by as much as 25 percent.

What’s more, these medications are considered “forever drugs,” requiring users to either maintain their dosage or regain most of the weight they lost.

Insurers are eager to draw a line between those seeking prescriptions for appearance’s sake and those at heightened risk of disease or death. They’re happy to cover the latter but, as with cosmetic surgery, insurers believe patients should foot the bill for the former.

Lost in this debate is an important question: Why not figure out how to make these lifesaving drugs broadly available and affordable?

The U.S. Government Can Lead The Way

With hundreds of thousands of obesity-related deaths each year, the magnitude of the problem qualifies as an “epidemic” and justifies forceful government intervention.

The current administration, with congressional approval, could initiate a nationwide campaign to fight obesity, similar to Operation Warp Speed. The program, with a $10 billion upfront investment, led to the speedy development of a safe and effective coronavirus vaccine. The government then was able to purchase more than one billion doses at one-third the cost of the vaccine’s current list price.

Here’s how the administration could replicate Operation Warp Speed to fight the obesity epidemic without breaking the bank.

Operation: Slim Provisions

The government would invest $4 billion up front— twice the average R&D cost to bring a new drug to market.

In return for funding and a ten year contract, the first drugmaker to develop a safe and effective weight-loss drug would be required to sell that medication back to the government at $40 per dose (or $2,000 per patient/year), significantly below the retail price of Ozempic and similar drugs. The winning pharma company would benefit financially, earning up to $1.2 trillion in sales over the contract’s lifetime without having to shoulder R&D costs.

With the new medication in hand, government-sponsored health programs, Medicaid and Medicare, would make it available to all obese enrollees (roughly 60 million people) for the next decade.

And by providing the drug to more than half of all obese adults, the government would reduce medical expenses by up to $130 billion annually or $1.3 trillion over 10 years, making the effort cost-neutral for American taxpayers.

Risks vs. Rewards

The only financial risk to the government (outside of defending likely lawsuits) would be failing in its search for a new drug, thus wasting the

$4 billion of taxpayer money. But that’s a relatively insignificant sum compared to the potential healthcare benefits.

The role of government is to protect the health and financial well-being of the nation. Fulfilling that function led to a lifesaving Covid-19 vaccine. Doing so again is the best option our nation has to address America’s growing obesity epidemic.

Read More

Handcuffs, taxes, law, police, enforcement, tax

ProPublica has obtained the blueprint for the Trump administration’s unprecedented plan to turn over IRS records to Homeland Security in order to speed up the agency’s mass deportation efforts.

Ricardo Tomás for ProPublica

The IRS Is Building a Vast System To Share Millions of Taxpayers’ Data With ICE

The Internal Revenue Service is building a computer program that would give deportation officers unprecedented access to confidential tax data.

ProPublica has obtained a blueprint of the system, which would create an “on demand” process allowing Immigration and Customs Enforcement to obtain the home addresses of people it’s seeking to deport.

Keep ReadingShow less
Defend Democracy Against Bombardments on the Elections Front –A Three-Part Series
low angle photography of beige building

Defend Democracy Against Bombardments on the Elections Front –A Three-Part Series

In Part One of this three-part series, Pat Merloe explored the impact of the political environment, the need for constitutional defense against power-grabbing, and the malign effects of proof of citizenship on voting.

In Part Two, Merloe explored the harmful effects of Executive Orders, the reversal of the Justice Department on voting rights, and the effects of political retribution.

Part Three: Attacks on the Courts, and the Need to Defend Universal and Equal Suffrage

As noted in Parts One and Two of this series, multipoint attacks against trustworthy elections are underway with just 16 months until 2026’s voting and less time before off-year elections this November. Awareness of the attacks – and those fortifying trustworthy processes – is crucial for defending democracy.

Keep ReadingShow less
Bay Area Social Media Post Claims ICE Cannot Enter Library, Fuels Misinformation

South Novato Library, California

Pricila Flores

Bay Area Social Media Post Claims ICE Cannot Enter Library, Fuels Misinformation

Bay Area community advocates are cautioning community members to be wary of what they see, interact with, and post on social media regarding information about the United States Immigration and Customs Enforcement (ICE) and immigration, following a rumor that targeted the Marin County Library.

‘South Novato Library has safe rooms that cannot be accessed by border patrol or ICE without a court order,’ an Instagram story post reads, with photos of a room in the library next to the text alongside the library address. The graphic claims Immigration and Customs Enforcement would not have the right to enter the pictured room without a court-ordered warrant.

Despite the graphic becoming a popular share among the local community of Novato, a Marin County city located just north of San Francisco, the information is false.

Keep ReadingShow less

Angelica Salas’s Journey From Undocumented Immigrant to Community Leader at CHIRLA

Angelica Salas has long been a leading advocate for immigrant rights in Los Angeles. Since becoming Executive Director of the Coalition for Humane Immigrant Rights of Los Angeles (CHIRLA) in 1999, she has transformed the organization into one of the most powerful immigrant-led advocacy groups in the country. Her leadership has redefined what grassroots organizing can look like, mobilizing communities around issues ranging from Deferred Action for Childhood Arrivals (DACA) to voter outreach and legal services.

Salas’s journey into activism is deeply personal. Born in Durango, Mexico, she arrived in the United States at the age of five, undocumented, to reunite with her parents who had migrated for work. Growing up in Pasadena, California, her family lived in the shadows of deportation until they were able to legalize their status. In 2008, Salas became a U.S. citizen, adding a powerful chapter to a story she shares with many of the people CHIRLA serves. Her own experience navigating the U.S. immigration system informs her commitment to building dignity, not dependency, in the immigrant rights movement. After graduating from Occidental College with a degree in history and sociology, Salas joined CHIRLA in 1995 and became its executive director just four years later.

Keep ReadingShow less